Quality Control Process for EQ-5D-5L Valuation Studies.
暂无分享,去创建一个
Mark Oppe | Elly Stolk | Juan M Ramos-Goñi | Bernhard Slaap | Jan J V Busschbach | J. Busschbach | E. Stolk | M. Oppe | J. Ramos-Goñi | B. Slaap
[1] Mark Oppe,et al. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[2] G. S. Radford,et al. The control of quality in manufacturing , 2007 .
[3] Mark Oppe,et al. Lead versus lag time trade-off variants: does it make any difference? , 2013 .
[4] Nan Luo,et al. The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework , 2013, The European Journal of Health Economics.
[5] Elvin Geng,et al. Implementation and Operational Research: Evaluating Outcomes of Patients Lost to Follow-up in a Large Comprehensive Care Treatment Program in Western Kenya , 2015, Journal of acquired immune deficiency syndromes.
[6] N. Devlin,et al. The development of new research methods for the valuation of EQ-5D-5L , 2013, The European Journal of Health Economics.
[7] M. Versteegh,et al. Introducing the composite time trade-off: a test of feasibility and face validity , 2013, The European Journal of Health Economics.
[8] Mark Oppe,et al. EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes , 2016, PharmacoEconomics.
[9] Aki Tsuchiya,et al. A comparison of alternative variants of the lead and lag time TTO. , 2013, Health economics.
[10] G. Bonsel,et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.
[11] David Parkin,et al. Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. , 2010, Health economics.
[12] E van der Schueren,et al. Quality control of validity of data collected in clinical trials. EORTC Study Group on Data Management (SGDM). , 1989, European journal of cancer & clinical oncology.
[13] Juan M Ramos-Goñi,et al. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[14] M De Pauw. Quality control in data monitoring of clinical trials. , 1994, Acta urologica Belgica.
[15] Mark Oppe,et al. Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid Approach , 2014, Medical care.
[16] G. Knatterud,et al. Methods of quality control and of continuous audit procedures for controlled clinical trials. , 1981, Controlled clinical trials.
[17] Angela Robinson,et al. Exploring challenges to TTO utilities: valuing states worse than dead. , 2006, Health economics.
[18] Jan Passchier,et al. Employing quality control and feedback to the EQ-5D-5L valuation protocol to improve the quality of data collection , 2016, Quality of Life Research.
[19] G Ardine de Wit,et al. Dutch Tariff for the Five-Level Version of EQ-5D. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.